Compare abrdn Income Credit Strategies Fund (ACP) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs IDEXX Laboratories, Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while IDEXX Laboratories, Inc. trades at $557.94 (market cap $44.98B). The key difference: IDEXX Laboratories, Inc. is far larger — about 68.5× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ACP | IDXX | |
|---|---|---|
Market Cap | $656.21M | $44.98B |
Sector | Financials | Health |
52-Week High | $5.98 | $766.68 |
52-Week Low | $5.01 | $514.61 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $45.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
IDXX trades at $570.25, up 2.23% today, with strong technical momentum as it approaches resistance near $572. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics. Analyst sentiment is bullish with a $645 consensus target, though elevated valuations pose a risk.
Outlook remains positive given consistent earnings beats and strategic AI integration, but high P/E of 41.57 suggests limited margin for error. Key risks include competitive pressures and reliance on pet healthcare spending cycles. Institutional ownership trends and upcoming Q2 earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
